Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
Publications
Publications
  • January 2021
  • Case
  • HBS Case Collection

Takeda Pharmaceutical Company Limited (A)

By: David J. Collis, Nobuo Sato and Akiko Kanno
  • Format:Print
  • | Language:English
  • | Pages:22
ShareBar

Abstract

This case follows Christophe Weber, President and CEO of Takeda Pharmaceutical Company Limited, a leading pharmaceutical company headquartered in Tokyo, Japan, as Takeda considers acquiring Shire Plc, a biotech company based in Ireland. The acquisition would turn Takeda into a top ten global pharmaceutical company; however, other pharma companies were showing initial interest in acquiring Shire, and the acquisition would require a large amount of funding. Other concerns about the bid were nonfinancial. Over the last two decades, Takeda had aggressively pursued globalization and was now a global company with two thirds of revenue raised outside Japan and a diverse management team. What was the implication of acquiring Shire? Was now the right time to take such a big step? Was the acquisition in line with the company’s goals? How would the combined company be managed? Would the acquisition put an end to Takeda as a Japanese company?

Keywords

Pharmaceutical Companies; Pharmaceutical Industry; Pharmaceuticals; Japan; Biotech; Biotechnology; M&a; Mergers & Acquisitions; Globalization; Management; Asia; R&d; Talent Management; Mergers And Acquisitions; Globalization; Global Strategy; Pharmaceutical Industry; Biotechnology Industry; Japan

Citation

Collis, David J., Nobuo Sato, and Akiko Kanno. "Takeda Pharmaceutical Company Limited (A)." Harvard Business School Case 721-373, January 2021.
  • Educators

About The Author

David J. Collis

Strategy
→More Publications

More from the Authors

    • February 2021
    • Faculty Research

    Shareholder Activists and Corporate Strategy

    By: David J. Collis and Caeden Brynie
    • 2021
    • Strategic Management Review

    The Virtues and Limitations of Dynamic Capabilities

    By: Bharat Anand and David J. Collis
    • January 2021
    • Faculty Research

    Takeda Pharmaceutical Company Limited (B)

    By: David J. Collis, Nobuo Sato and Akiko Kanno
More from the Authors
  • Shareholder Activists and Corporate Strategy By: David J. Collis and Caeden Brynie
  • The Virtues and Limitations of Dynamic Capabilities By: Bharat Anand and David J. Collis
  • Takeda Pharmaceutical Company Limited (B) By: David J. Collis, Nobuo Sato and Akiko Kanno
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Digital Accessibility
Copyright © President & Fellows of Harvard College